The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Genetic and epigenetic changes in DNA are involved in cancer development and tumor
progression. Histone deacetylases (HDACs) are key regulators of gene expression that act …

Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …

Epigenetic enzymes are often dysregulated in human tumors through mutation, altered
expression, or inappropriate recruitment to certain loci. The identification of these enzymes …

Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD
salvage pathway of mammalian cells and is overexpressed in numerous types of cancers …

Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven
metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …

Cancer initiation and progression are the result of genetic and/or epigenetic alterations.
Acetylation-mediated histone/non-histone protein modification plays an important role in the …

Histone deacetylases comprise a family of 18 genes, which are grouped into classes I–IV
based on their homology to their respective yeast orthologues. Classes I, II, and IV consist of …